Purvalanol A, 10 mg

From STEMCELL Technologies, this cell-permeable compound is a potent and selective inhibitor of cyclin-dependent kinases (CDKs), known as Purvalanol A. It acts through competitive inhibition of ATP binding, targeting CDK1/cyclin B (IC50 = 4 nM), CDK2/cyclin A (IC50 = 70 nM), CDK2/cyclin E (IC50 = 35 nM), CDK4/cyclin D1 (IC50 = 850 nM), and CDK5/p35 (IC50 = 75 nM), thereby arresting cells in G1 and G2 phases of the cell cycle. The compound is supplied as a crystalline solid with a molecular weight of 388.9 g/mol and a molecular formula of C19H25ClN6O, with a reported purity of ≥ 98%.

Reported solubilities are approximately 0.2 mg/mL in a 1:5 solution of DMF:PBS (pH 7.2), ~10 mg/mL in EtOH, ~30 mg/mL in DMSO, and ~50 mg/mL in DMF, with low solubility in aqueous media. The product is stable at -20°C as supplied and should be protected from prolonged exposure to light; for long-term storage, a desiccant is recommended. As supplied, it is stable for 12 months from date of receipt. Stock solutions in DMSO should be prepared fresh, stored at -20°C, and aliquoted to avoid repeated freeze-thaw cycles. When used as a cell culture supplement, the final DMSO concentration should be kept below 0.1% to avoid potential cell toxicity.

Published applications in cancer research include inhibition of proliferation in exponentially growing cancer cell lines, induction of apoptosis in MCF-7 estrogen receptor positive breast cancer cells, and suppression of cancer progression associated with Src up-regulation through coordinated inhibition of cell cycle progression and tyrosine kinase signaling. Per the safety data sheet, this chemical is not classified as hazardous according to the GHS or the 2012 OSHA Hazard Communication Standard.